Compounded Injectable Semaglutide: Everything You Need to Know Before Starting
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist — a class of medications that has produced some of the most significant advances in obesity medicine in a generation. Originally developed for type 2 diabetes management, clinical trials demonstrated weight loss effects that far exceeded any previously approved pharmacological intervention.
Compounded semaglutide provides access to this therapy through licensed compounding pharmacies under physician prescription, typically with B12 or other additives, at a cost structure that makes ongoing treatment feasible for more patients.
How GLP-1 Receptor Agonism Works
GLP-1 is a naturally occurring incretin hormone secreted by L-cells in the intestine after eating. It plays multiple roles in metabolic regulation:
Appetite suppression:: GLP-1 acts on the hypothalamus to reduce hunger and increase satiety signals
Delayed gastric emptying:: Slows the rate at which food leaves the stomach, prolonging fullness
Insulin secretion:: Stimulates glucose-dependent insulin release, reducing postprandial blood sugar
Glucagon suppression:: Reduces glucagon secretion, lowering hepatic glucose output
Reward pathway modulation:: Reduces dopaminergic food reward signals in the brain
Semaglutide mimics GLP-1 but with a half-life of approximately 7 days — enabling once-weekly dosing vs. the minutes-long action of endogenous GLP-1.
Clinical Evidence
The SUSTAIN and STEP trial programs documented semaglutide's efficacy in tens of thousands of patients:
STEP 1 (68 weeks, 2.4mg weekly): **14.9% average body weight reduction** vs. 2.4% for placebo
SUSTAIN-6 (cardiovascular outcomes): Significant reduction in major cardiovascular events in T2D patients with established CVD
STEP 5 (104 weeks): Weight loss maintained beyond two years with continued treatment
Compounded vs. Brand-Name Semaglutide
Compounded semaglutide is not FDA-approved and is not the same formulation as the FDA-approved branded versions. It is prepared by licensed 503B or 503A compounding pharmacies under physician prescription and is subject to state pharmacy board oversight. The active molecule — semaglutide — is the same, but compounded formulations have not undergone FDA review for safety and efficacy as standalone products.
Patients in physician-supervised programs receive medication with syringes and all supplies needed for self-administration.
Compounded injectable semaglutide is a prescription medication. Not everyone qualifies. Eligibility is determined by a licensed provider based on BMI, medical history, and health goals.
